191 related articles for article (PubMed ID: 3545436)
1. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
4. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
Maeda K; Jimbow K
Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody (AFH1) immunoreactive on morphologically abnormal basal melanocytes within dysplastic nevi, nevocellular nevus nests, and melanoma.
Aronson PJ; Ito K; Fukaya T; Hashimoto K; Mehregan AH
J Invest Dermatol; 1988 Apr; 90(4):452-8. PubMed ID: 3280697
[TBL] [Abstract][Full Text] [Related]
6. Specification and use of a mouse monoclonal antibody raised against melanosomes for the histopathologic diagnosis of amelanotic malignant melanoma.
Maeda K; Maeda K; Jimbow K
Cancer; 1988 Sep; 62(5):926-34. PubMed ID: 3044572
[TBL] [Abstract][Full Text] [Related]
7. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
8. KP1 (CD 68) staining of malignant melanomas.
Facchetti F; Bertalot G; Grigolato PG
Histopathology; 1991 Aug; 19(2):141-5. PubMed ID: 1757067
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits.
Cho KH; Hashimoto K; Taniguchi Y; Pietruk T; Zarbo RJ; An T
Cancer; 1990 Aug; 66(4):765-71. PubMed ID: 2201426
[TBL] [Abstract][Full Text] [Related]
10. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.
Holzmann B; Johnson JP; Kaudewitz P; Riethmüller G
J Exp Med; 1985 Feb; 161(2):366-77. PubMed ID: 3973533
[TBL] [Abstract][Full Text] [Related]
11. Beta 2 microglobulin expression in normal melanocytes, nevocellular nevi, and malignant melanomas.
Takata M; Hirone T; Matsumura H
J Invest Dermatol; 1989 May; 92(5 Suppl):243S-247S. PubMed ID: 2654298
[TBL] [Abstract][Full Text] [Related]
12. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
13. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
[TBL] [Abstract][Full Text] [Related]
14. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
Kornstein MJ; Brooks JS; Elder DE
Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical reactivity of the antimelanoma monoclonal antibody MEL-1.
Clemente C
Tumori; 1985 Jun; 71(3):225-32. PubMed ID: 3895683
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness.
Sagebiel RW
J Invest Dermatol; 1993 Mar; 100(3):322S-325S. PubMed ID: 8440914
[TBL] [Abstract][Full Text] [Related]
18. Expression of ligands to NKp46 in benign and malignant melanocytes.
Cagnano E; Hershkovitz O; Zilka A; Bar-Ilan A; Golder A; Sion-Vardy N; Bogdanov-Berezovsky A; Mandelboim O; Benharroch D; Porgador A
J Invest Dermatol; 2008 Apr; 128(4):972-9. PubMed ID: 17972960
[TBL] [Abstract][Full Text] [Related]
19. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.
Trefzer U; Rietz N; Chen Y; Audring H; Herberth G; Siegel P; Reinke S; Königer P; Wu S; Ma J; Liu Y; Wang H; Sterry W; Guo Y
Arch Dermatol Res; 2000 Dec; 292(12):583-9. PubMed ID: 11214818
[TBL] [Abstract][Full Text] [Related]
20. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
